“Tools for continuous health monitoring and closed-loop therapies“
The Global Burden of Disease Study 2010 (GBD 2010) estimated that a substantial proportion of the world’s disease burden came from neurological, mental, mood disorders, and substance abuse. In 2010, mental and substance abuse disorders accounted for about 10% of the global burden of disease and were the leading cause of years lived with disability among all disease groups. The COVID pandemic exacerbated this trend and resulted in 1 out of 4 people in the US to have a mental health condition. Continuous monitoring of disease markers has the potential to create new insights on disease conditions and improve outcomes with early diagnosis and monitoring of disease treatments. New tools based on nanotechnology and artificial intelligence have the potential to make a significant mark in neurological, and in mental health conditions.
In this talk, I will describe advances in tools and materials that can enable the continuous monitoring of biomarkers of disease. I will provide several examples of artificial intelligence and nanoscale platforms that can be a game changer for patients with neurological and mental health conditions.
Lili Deligianni was for three decades at IBM’s Thomas J. Watson Research Center in Yorktown Heights, New York. Dr. Deligianni played a leading role in the successful introduction of electrochemical processes in the solder bump technology. The process became the standard in the electronic industry for joining of silicon chips to packages. She co-invented and developed the copper electrodeposition process for on-chip interconnects. The introduction of electroplated copper interconnects has revolutionized the performance of computer chips. For the patents associated with the copper interconnect process, she received the 2006 Inventor of the Year Award of the New York Intellectual Property Law Association and IBM Corporate Awards. For these technologies, the IBM team was recognized in 2004 with the US National Medal of Technology and Innovation.
Dr. Deligianni has co-authored 62 peer-reviewed publications and 230 issued and pending patents. Lili Deligianni received her PhD degree in Chemical Engineering from the University of Illinois in Urbana-Champaign. She is an elected member of the IBM Academy of Technology. She is a Fellow of the Electrochemical Society, was the first female recipient of the Vittorio de Nora Award of the Electrochemical Society, and a recipient of the E.V. Murphree Award of the American Chemical Society.
She is a senior member of IEEE and of AIChE. She is a member of ACS, AAAS, served as chair of the Watson Women’s Network at IBM, and co-chairs the Women at NAE meetings. She organized and participated for many years in Engineers Week outreach in K-12 schools.
Dr. Deligianni has a proven track record in R&D and commercialization of electronic components for the semiconductor industry. She has worked on a wide range of research including a DNA sequencing, nanoscale tools that can be integrated with traditional electronics to create bioelectronic therapies of the nervous system, and more recently, on addiction. Her current research interests include biosensors, bioelectronics, and artificial intelligence with applications in neural and mental health.